Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Global Forecast 2019-2023
SKU ID : TNV-14439887 | Publishing Date : 28-Jun-2019 | No. of pages : 125
Detailed TOC of Age-Related Macular Degeneration (AMD) Therapeutics Market by Type and Geography - Global Forecast 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Wet AMD - Market size and forecast 2018-2023
Dry AMD - Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Strategic alliances
Development of gene therapy for AMD
Growing awareness about AMD
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Amgen Inc.
Bausch Health Companies Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Wet AMD - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Wet AMD - Year-over-year growth 2019-2023 (%)
Exhibit 21: Dry AMD - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Phase III drugs for dry AMD
Exhibit 23: Cell therapies under development for dry AMD
Exhibit 24: Dry AMD - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by type
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Population aged 65 years and above (% of total) in Asia 2017
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Some late-stage drugs for treatment of AMD
Exhibit 45: Global growth in geriatric population 2013-2017 (%)
Exhibit 46: Approximate cost of AMD drugs
Exhibit 47: Companies developing biosimilars: Overview
Exhibit 48: Side effects associated with drugs used for AMD
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: Amgen Inc. - Vendor overview
Exhibit 56: Amgen Inc. - Business segments
Exhibit 57: Amgen Inc. - Organizational developments
Exhibit 58: Amgen Inc. - Geographic focus
Exhibit 59: Amgen Inc. - Key offerings
Exhibit 60: Amgen Inc. - Key customers
Exhibit 61: Bausch Health Companies Inc. - Vendor overview
Exhibit 62: Bausch Health Companies Inc. - Business segments
Exhibit 63: Bausch Health Companies Inc. - Organizational developments
Exhibit 64: Bausch Health Companies Inc. - Geographic focus
Exhibit 65: Bausch Health Companies Inc. - Segment focus
Exhibit 66: Bausch Health Companies Inc. - Key offerings
Exhibit 67: Bausch Health Companies Inc. - Key customers
Exhibit 68: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 69: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 70: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 71: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 72: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 73: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 74: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 75: Novartis AG - Vendor overview
Exhibit 76: Novartis AG - Business segments
Exhibit 77: Novartis AG - Organizational developments
Exhibit 78: Novartis AG - Geographic focus
Exhibit 79: Novartis AG - Segment focus
Exhibit 80: Novartis AG - Key offerings
Exhibit 81: Novartis AG - Key customers
Exhibit 82: Regeneron Pharmaceuticals Inc. - Vendor overview
Exhibit 83: Regeneron Pharmaceuticals Inc. - Business segments
Exhibit 84: Regeneron Pharmaceuticals Inc. - Organizational developments
Exhibit 85: Regeneron Pharmaceuticals Inc. - Geographic focus
Exhibit 86: Regeneron Pharmaceuticals Inc. - Key offerings
Exhibit 87: Regeneron Pharmaceuticals Inc. - Key customers
Exhibit 88: Validation techniques employed for market sizing
Exhibit 89: Definition of market positioning of vendors